328 related articles for article (PubMed ID: 25510262)
1. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
Gabriel D; Roedl D; Gordon LB; Djabali K
Aging Cell; 2015 Feb; 14(1):78-91. PubMed ID: 25510262
[TBL] [Abstract][Full Text] [Related]
2. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
3. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype.
Gabriel D; Gordon LB; Djabali K
PLoS One; 2016; 11(12):e0168988. PubMed ID: 28033363
[TBL] [Abstract][Full Text] [Related]
5. Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.
Eisch V; Lu X; Gabriel D; Djabali K
Oncotarget; 2016 Apr; 7(17):24700-18. PubMed ID: 27015553
[TBL] [Abstract][Full Text] [Related]
6. Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts.
Gabriel D; Shafry DD; Gordon LB; Djabali K
Oncotarget; 2017 Sep; 8(39):64809-64826. PubMed ID: 29029393
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
8. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
[TBL] [Abstract][Full Text] [Related]
9. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
[TBL] [Abstract][Full Text] [Related]
10. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
McClintock D; Gordon LB; Djabali K
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.
Cao K; Graziotto JJ; Blair CD; Mazzulli JR; Erdos MR; Krainc D; Collins FS
Sci Transl Med; 2011 Jun; 3(89):89ra58. PubMed ID: 21715679
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide Y Enhances Progerin Clearance and Ameliorates the Senescent Phenotype of Human Hutchinson-Gilford Progeria Syndrome Cells.
Aveleira CA; Ferreira-Marques M; Cortes L; Valero J; Pereira D; Pereira de Almeida L; Cavadas C
J Gerontol A Biol Sci Med Sci; 2020 May; 75(6):1073-1078. PubMed ID: 32012215
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
14. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Bergo MO; Toth JI; Qiao X; Hu Y; Sandoval S; Meta M; Bendale P; Gelb MH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10291-6. PubMed ID: 16014412
[TBL] [Abstract][Full Text] [Related]
15. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
[TBL] [Abstract][Full Text] [Related]
16. Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition.
Marji J; O'Donoghue SI; McClintock D; Satagopam VP; Schneider R; Ratner D; Worman HJ; Gordon LB; Djabali K
PLoS One; 2010 Jun; 5(6):e11132. PubMed ID: 20559568
[TBL] [Abstract][Full Text] [Related]
17. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
18. Nuclear lamins and progerin are dispensable for antioxidant Nrf2 response to arsenic and cadmium.
Hashimoto K; Majumdar R; Tsuji Y
Cell Signal; 2017 May; 33():69-78. PubMed ID: 28229933
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
[TBL] [Abstract][Full Text] [Related]
20. All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype.
Pellegrini C; Columbaro M; Capanni C; D'Apice MR; Cavallo C; Murdocca M; Lattanzi G; Squarzoni S
Oncotarget; 2015 Oct; 6(30):29914-28. PubMed ID: 26359359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
